AU2016291558A1 - Markers of stroke and stroke severity - Google Patents

Markers of stroke and stroke severity Download PDF

Info

Publication number
AU2016291558A1
AU2016291558A1 AU2016291558A AU2016291558A AU2016291558A1 AU 2016291558 A1 AU2016291558 A1 AU 2016291558A1 AU 2016291558 A AU2016291558 A AU 2016291558A AU 2016291558 A AU2016291558 A AU 2016291558A AU 2016291558 A1 AU2016291558 A1 AU 2016291558A1
Authority
AU
Australia
Prior art keywords
biomarkers
ischemic stroke
subject
group
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016291558A
Other languages
English (en)
Inventor
Taura L. Barr
Richard GIERSCH
Grant O'CONNELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Virginia University filed Critical West Virginia University
Publication of AU2016291558A1 publication Critical patent/AU2016291558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
AU2016291558A 2015-07-10 2016-07-08 Markers of stroke and stroke severity Abandoned AU2016291558A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562191096P 2015-07-10 2015-07-10
US62/191,096 2015-07-10
US201662300342P 2016-02-26 2016-02-26
US62/300,342 2016-02-26
US201662352680P 2016-06-21 2016-06-21
US62/352,680 2016-06-21
PCT/US2016/041585 WO2017011329A1 (fr) 2015-07-10 2016-07-08 Marqueurs d'accident vasculaire cérébral et de gravité d'accident vasculaire cérébral

Publications (1)

Publication Number Publication Date
AU2016291558A1 true AU2016291558A1 (en) 2018-02-08

Family

ID=57757734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016291558A Abandoned AU2016291558A1 (en) 2015-07-10 2016-07-08 Markers of stroke and stroke severity

Country Status (8)

Country Link
US (1) US20190017117A1 (fr)
EP (1) EP3320132A4 (fr)
JP (1) JP2018523469A (fr)
CN (1) CN108291330A (fr)
AU (1) AU2016291558A1 (fr)
CA (1) CA2992139A1 (fr)
GB (1) GB2556004A (fr)
WO (1) WO2017011329A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
EP3625357A4 (fr) * 2017-05-16 2021-02-24 The Chinese University Of Hong Kong Analyse intégrative d'arn de plasma acellulaire et monocellulaire
GB2563414A (en) * 2017-06-14 2018-12-19 Randox Laboratories Ltd Improvements in stroke diagnostics
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
MY202410A (en) 2017-09-01 2024-04-27 Venn Biosciences Corp Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
EP3697925A4 (fr) * 2017-10-18 2021-06-23 Venn Biosciences Corporation Identification et utilisation de paramètres biologiques pour le diagnostic et la surveillance d'un traitement
AU2019270404A1 (en) * 2018-05-16 2020-12-10 Centre Hospitalier Régional Et Universitaire De Brest Blood biomarkers of stroke
WO2020131955A1 (fr) * 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Évaluation du risque avec l'adn acellulaire total
US20220107323A1 (en) * 2019-01-30 2022-04-07 Inserm(Institut National De La Santé Et De La Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
EP3935581A4 (fr) 2019-03-04 2022-11-30 Iocurrents, Inc. Compression et communication de données à l'aide d'un apprentissage automatique
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
CN110208413B (zh) * 2019-06-18 2021-09-28 中国药科大学 血清生物标志物在制备issu的诊断试剂中的应用
RU2715557C1 (ru) * 2019-06-24 2020-03-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) Способ обнаружения внеклеточной днк в цельной периферической крови
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
WO2021072404A1 (fr) * 2019-10-10 2021-04-15 University Of Kentucky Research Foundation Algorithme d'apprentissage automatique pour prédire des résultats cliniques et pour identifier des cibles de médicament lors d'un accident ischémique cérébral
CA3189613A1 (fr) 2020-08-17 2022-02-24 Raul DE MACEDO QUEIXADA Dispositif et procede de mesure du niveau de biomarqueurs et de pathogenes dans des substances
CN112396591A (zh) * 2020-11-25 2021-02-23 暨南大学附属第一医院（广州华侨医院） 一种基于腰椎x线图像的骨质疏松智能评估方法
RU2767929C1 (ru) * 2021-07-07 2022-03-22 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ диагностики степени тяжести ишемического инсульта
CN117116471B (zh) * 2023-10-23 2024-01-23 四川大学华西医院 建立预测增殖或非增殖狼疮肾炎模型的方法及预测方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (fr) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Anticorps contre des complexes de recepteurs de ligand et des ligands ainsi que leur utilite dans des dosages ligands-recepteurs
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
EP0585310B1 (fr) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Inhibiteurs de "liaison croisee" et leurs utilisations
EP0579767B1 (fr) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Nouveaux conjugues et dosages destines a la detection simultanee de ligands multiples
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP2002510505A (ja) 1998-04-03 2002-04-09 フィロス インク． 位置特定可能な蛋白質アレイ
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7022478B2 (en) * 2002-05-14 2006-04-04 The Chinese University Of Hong Kong Methods for evaluating stroke or cardiac ischemia by nucleic acid detection
EP2152907A1 (fr) * 2007-05-01 2010-02-17 The Regents of the University of California Procédés de diagnostic d'ischémie
WO2009018335A2 (fr) * 2007-07-30 2009-02-05 The General Hospital Corporation Ciblage de cellules de cerveau par administration ophtalmique
CN101245392B (zh) * 2008-03-25 2010-12-01 中国医学科学院阜外心血管病医院 一种预测出血性脑卒中易感性的方法及试剂盒
EP2166358A1 (fr) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Biomarqueurs de diagnostic différentiel de conditions simulant l'accident vasculaire cérébral et ses procédés d'utilisation
US20120135874A1 (en) * 2009-05-08 2012-05-31 The Johns Hopkins University Single molecule spectroscopy for analysis of cell-free nucleic acid biomarkers
CN102108387A (zh) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 通过检测叶酸代谢障碍预防脑卒中发生的方法
US9200322B2 (en) * 2010-02-23 2015-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for acute ischemic stroke
CA2804763C (fr) * 2010-07-14 2023-01-03 The Regents Of The University Of California Biomarqueurs utilises pour le diagnostic d'accidents ischemiques transitoires
US20120184449A1 (en) * 2010-12-23 2012-07-19 Sequenom, Inc. Fetal genetic variation detection
CA2847903C (fr) * 2011-09-30 2020-10-27 Somalogic, Inc. Prediction d'evenement de risque cardio-vasculaire et utilisations de celle-ci
CA2914193A1 (fr) * 2013-06-20 2014-12-24 Immunexpress Pty Ltd Identification de marqueur biologique
CN103421905A (zh) * 2013-08-20 2013-12-04 张飚 从血液中检测用于诊断脑卒中的microRNA的方法
KR101523769B1 (ko) * 2013-11-13 2015-05-27 한국생명공학연구원 허혈성 뇌졸중 진단용 다중 snp 및 이의 용도

Also Published As

Publication number Publication date
CN108291330A (zh) 2018-07-17
WO2017011329A1 (fr) 2017-01-19
GB2556004A (en) 2018-05-16
JP2018523469A (ja) 2018-08-23
US20190017117A1 (en) 2019-01-17
EP3320132A4 (fr) 2018-11-21
GB201802155D0 (en) 2018-03-28
CA2992139A1 (fr) 2017-01-19
EP3320132A1 (fr) 2018-05-16

Similar Documents

Publication Publication Date Title
AU2016291558A1 (en) Markers of stroke and stroke severity
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
JP6550124B2 (ja) 自閉症スペクトラム障害のリスクを決定するための方法およびシステム
Quinn et al. Extracellular RNAs: development as biomarkers of human disease
US20200300853A1 (en) Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
US20180004895A1 (en) COPD Biomarker Signatures
US9423403B2 (en) Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
Luo et al. Identification of circular RNAs hsa_circ_0044235 and hsa_circ_0068367 as novel biomarkers for systemic lupus erythematosus
KR20200055804A (ko) 심혈관 위험 사건 예측 및 그것의 용도
JP2015514227A (ja) 結核バイオマーカーおよびその使用
KR20180105156A (ko) 비알코올성 지방간 질환 (nafld)과 비알코올성 지방간염 (nash) 생물마커 및 이들의 용도
US10859573B2 (en) Nourin molecular biomarkers diagnose angina patients with negative troponin
US11854701B2 (en) Time window-based platform for the rapid stratification of blunt trauma patients into distinct outcome cohorts
WO2010118210A1 (fr) Méthodes de prévision d'une complication et d'une chirurgie dans la maladie de crohn
JP2023145708A (ja) 関節リウマチ患者における心筋梗塞および重篤な感染リスクを評価するためのバイオマーカおよび方法
US20170052200A1 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
US20200165677A1 (en) Methods and uses of inflammatory bowel disease biomarkers
US10078089B2 (en) Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome
US20190311789A1 (en) Computer implemented discovery of biomarkers for blood brain barrier disruption
US20210214793A1 (en) Blood biomarkers of stroke
EP3655433A1 (fr) Procédés et utilisations de biomarqueurs de maladie intestinale inflammatoire
KR20220094201A (ko) 혈액 rna 편집 바이오마커에 의한 양극성 장애와 단극성 우울증의 감별 진단
US11402378B2 (en) Biomarkers and methods for assessing response to inflammatory disease therapy
CA3108159A1 (fr) Compositions et procedes de detection du cancer de la prostate
EP3756008A1 (fr) Découverte mise en oeuvre par ordinateur de signatures d'anticorps

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application